Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 4/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761192 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL10106427 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL1023170 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL641026 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL19082743 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219189 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL219188 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL22433392 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL20636193 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL6157512 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210300927-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | ARDELYX, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-9670209-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160039819-A1 | MUSCARINIC AGONISTS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | CHRM2 1180/4885CHRM1 492/4885CHRM3 1795/4885 |
| US-20210300927-A1 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS | FXR1, FXR2, NR1H4 | CHRM2 1180/4885CHRM1 492/4885CHRM3 1795/4885 |
| US-20160039819-A1 | MUSCARINIC AGONISTS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | CHRM2 2244/4885CHRM1 2211/4885CHRM3 975/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | CHRM2 1266/4885CHRM1 1892/4885CHRM3 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.